Aggregation risk prediction for antibodies and its application to biotherapeutic development
Open accessAbstract
Aggregation is a common problem affecting biopharmaceutical development that can have a significant effect on the quality of the product, as well as the safety to patients, particularly because of the increased risk of immune reactions. Here, we describe a new high-throughput screening algorithm developed to classify antibody molecules based on their propensity to aggregate. The tool, constructed and validated on experimental aggregation data for over 500 antibodies, is able to discern molecules with a high aggregation propensity as defined by experimental criteria relevant to bioprocessing and manufacturing of these molecules. Furthermore, we show how this tool can be combined with other computational approaches during early drug development to select molecules with reduced risk of aggregation and optimal developability properties.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are pharmaceutically focused computational approaches that aid in assessing the immunogenicity and biophysical properties of antibodies.
“There are also pharmaceutically focused computational approaches that aid in assessing the immunogenicity [14] and biophysical properties [15] of antibodies.”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [15]
The Adaptive Boosting model for aggregation prediction was trained and validated on a dataset of 500 antibodies with calculated biophysical properties.
“The model was trained and validated on a dataset of 500 antibodies with calculated biophysical properties.”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [15]
Obrezanova and colleagues used an extended set of physico-chemical parameters to create an Adaptive Boosting model for aggregation prediction.
“An extended set of physico-chemical parameters was used by Obrezanova and colleagues [15] to create an Adaptive Boosting model for aggregation prediction.”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 32 · Cited by 107
Research works printed but not linked: 3
- [12]Zurdo J, Michael R, Stallwood Y, Hedman K, Aastrup T Improving the developability of biopharmaceuticals. Inno Pharma Technol 2011; 37: 34- 40.
- [25]Lonza Biologics Epibase™ Immunogenicity Assessment Page [Internet]. Cambridge, UK: Lonza Biologics; 2014 [cited 2014 Oct 7] Available from: http://www.lonza.com/custom-manufacturing/development-technologies/protein-and-vaccine-development-services/immunogenicity-platforms.aspx
- [28]Zurdo J Surviving the valley of death. Eur Biopharmaceutical Rev 2013; 195: 50- 4.
- Authors
- Obrezanova, O., Arnell, A., de la Cuesta, R. G., Berthelot, M. E., Gallagher, T. R., Zurdo, J., & Stallwood, Y.
- Affiliations
- Lonza (United Kingdom) (GB)
- Corresponding author
- Obrezanova, Olga
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-03-04
- Volume
- 7
- Issue
- 2
- Pages
- 352-363
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC4622581
- OpenAlex
- W1516451386
- Cited by
- 107
- References
- 32
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 11 · 2023: 8 · 2022: 9 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 11 · 2017: 11 · 2016: 3 · 2015: 3
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- mAbs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- antibody aggregation, high-throughput screening, biologic therapy, developability, biopharmaceutical quality, bioprocessing, early drug development, computational screening
- MeSH terms
- Algorithms, Antibodies, Humans, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
